{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:12:20Z","timestamp":1788502340133,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"DOI":"10.1007\/s00417-026-07492-x","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:26:28Z","timestamp":1788499588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adoption patterns of anti-vascular endothelial growth factor therapies in retinal disease"],"prefix":"10.1007","author":[{"given":"Michael","family":"Kozlov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1772-3558","authenticated-orcid":false,"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"9","key":"7492_CR1","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.oret.2022.03.021","volume":"6","author":"TA Ciulla","year":"2022","unstructured":"Ciulla TA, Hussain RM, Taraborelli D et al (2022) Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outcomes in 130 247 Eyes. Ophthalmol Retina 6(9):796\u2013806. https:\/\/doi.org\/10.1016\/j.oret.2022.03.021","journal-title":"Ophthalmol Retina"},{"issue":"14","key":"7492_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1167\/iovs.62.14.26","volume":"62","author":"PA Campochiaro","year":"2021","unstructured":"Campochiaro PA (2021) Retinal and Choroidal Vascular Diseases: Past, Present, and Future: The 2021 Proctor Lecture. Invest Ophthalmol Vis Sci 62(14):26. https:\/\/doi.org\/10.1167\/iovs.62.14.26","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"7492_CR3","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.3390\/ijms26114992","volume":"26","author":"A Callan","year":"2025","unstructured":"Callan A, Heckman J, Tah G et al (2025) VEGF in Diabetic Retinopathy and Age-Related Macular Degeneration. Int J Mol Sci 26(11):4992. https:\/\/doi.org\/10.3390\/ijms26114992","journal-title":"Int J Mol Sci"},{"issue":"1","key":"7492_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1124\/jpet.122.001563","volume":"386","author":"A Muniyandi","year":"2023","unstructured":"Muniyandi A, Hartman GD, Song Y et al (2023) Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease. J Pharmacol Exp Ther 386(1):15\u201325. https:\/\/doi.org\/10.1124\/jpet.122.001563","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"7492_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2174\/1573399811666150615151324","volume":"17","author":"C Campa","year":"2016","unstructured":"Campa C, Alivernini G, Bolletta E et al (2016) Anti-VEGF Therapy for Retinal Vein Occlusions. Curr Drug Targets 17(3):328\u2013336. https:\/\/doi.org\/10.2174\/1573399811666150615151324","journal-title":"Curr Drug Targets"},{"issue":"8","key":"7492_CR6","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3390\/ph16081140","volume":"16","author":"A Hang","year":"2023","unstructured":"Hang A, Feldman S, Amin AP et al (2023) Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders. Pharmaceuticals (Basel) 16(8):1140. https:\/\/doi.org\/10.3390\/ph16081140","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"7492_CR7","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41433-021-01766-w","volume":"36","author":"F Ghanchi","year":"2022","unstructured":"Ghanchi F, Bourne R, Downes SM et al (2022) An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma. Eye (Lond) 36(6):1154\u20131167. https:\/\/doi.org\/10.1038\/s41433-021-01766-w","journal-title":"Eye (Lond)"},{"issue":"5","key":"7492_CR8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.18553\/jmcp.2025.24340","volume":"31","author":"JD Chambers","year":"2025","unstructured":"Chambers JD, Beinfeld MT, Richardson T, Pangrace M (2025) Assessing variation in US payer coverage of anti-vascular endothelial growth factor therapies for the treatment of age-related macular degeneration, diabetic retinopathy, and diabetic macular edema. J Manag Care Spec Pharm 31(5):451\u2013460. https:\/\/doi.org\/10.18553\/jmcp.2025.24340","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"7492_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/pharmaceutics14020265","volume":"14","author":"D Veritti","year":"2022","unstructured":"Veritti D, Sarao V, Gorni G, Lanzetta P (2022) Anti-VEGF Drugs Dynamics: Relevance for Clinical Practice. Pharmaceutics 14(2):265. https:\/\/doi.org\/10.3390\/pharmaceutics14020265","journal-title":"Pharmaceutics"},{"issue":"5","key":"7492_CR10","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3390\/cells10051049","volume":"10","author":"JO Wallsh","year":"2021","unstructured":"Wallsh JO, Gallemore RP (2021) Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options. Cells 10(5):1049. https:\/\/doi.org\/10.3390\/cells10051049","journal-title":"Cells"},{"key":"7492_CR11","doi-asserted-by":"publisher","unstructured":"Bryan JM, Sheth N, Heiferman MJ Trends in Anti-Vascular Endothelial Growth Factor Injections Among Medicare Part B Beneficiaries in 2013\u20132021 and the Step Therapy Era. J Vitreoretin Dis. https:\/\/doi.org\/10.1177\/24741264251383410","DOI":"10.1177\/24741264251383410"},{"issue":"1","key":"7492_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10384-022-00969-2","volume":"67","author":"Y Hashimoto","year":"2023","unstructured":"Hashimoto Y, Okada A, Matsui H et al (2023) Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan. Jpn J Ophthalmol 67(1):109\u2013118. https:\/\/doi.org\/10.1007\/s10384-022-00969-2","journal-title":"Jpn J Ophthalmol"},{"issue":"11","key":"7492_CR13","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1007\/s00417-024-06531-9","volume":"262","author":"H Agostini","year":"2024","unstructured":"Agostini H, Abreu F, Baumal CR et al (2024) Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes. Graefes Arch Clin Exp Ophthalmol 262(11):3437\u20133451. https:\/\/doi.org\/10.1007\/s00417-024-06531-9","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"7492_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/2474126420930863","volume":"4","author":"AJ Witkin","year":"2020","unstructured":"Witkin AJ, Hahn P, Murray TG et al (2020) Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab. J Vitreoretin Dis 4(4):269\u2013279. https:\/\/doi.org\/10.1177\/2474126420930863","journal-title":"J Vitreoretin Dis"},{"issue":"14","key":"7492_CR15","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.3390\/jcm12144671","volume":"12","author":"JG Garweg","year":"2023","unstructured":"Garweg JG, Keiper J, Pfister IB, Schild C (2023) Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment-A Meta-Analysis and Systematic Review. J Clin Med 12(14):4671. https:\/\/doi.org\/10.3390\/jcm12144671","journal-title":"J Clin Med"},{"issue":"6","key":"7492_CR16","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1080\/09273948.2025.2476061","volume":"33","author":"MH Nowroozzadeh","year":"2025","unstructured":"Nowroozzadeh MH, Hajipourkhorasani M (2025) Increased Risk of Retinal Vasculitis May Be Associated with Aflibercept 8\u00a0mg: A Pharmacovigilance Analysis of the FAERS Database. Ocul Immunol Inflamm 33(6):1056\u20131058. https:\/\/doi.org\/10.1080\/09273948.2025.2476061","journal-title":"Ocul Immunol Inflamm"},{"issue":"47","key":"7492_CR17","doi-asserted-by":"publisher","first-page":"18898","DOI":"10.1073\/pnas.1319482110","volume":"110","author":"BT Walters","year":"2013","unstructured":"Walters BT, Mayne L, Hinshaw JR et al (2013) Folding of a large protein at high structural resolution. Proc Natl Acad Sci USA 110(47):18898\u201318903. https:\/\/doi.org\/10.1073\/pnas.1319482110","journal-title":"Proc Natl Acad Sci USA"},{"key":"7492_CR18","doi-asserted-by":"publisher","first-page":"1298473","DOI":"10.1155\/2016\/1298473","volume":"2016","author":"A Kuriakose","year":"2016","unstructured":"Kuriakose A, Chirmule N, Nair P (2016) Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications. J Immunol Res 2016:1298473. https:\/\/doi.org\/10.1155\/2016\/1298473","journal-title":"J Immunol Res"},{"issue":"5","key":"7492_CR19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.oret.2022.11.010","volume":"7","author":"NA Patel","year":"2023","unstructured":"Patel NA, Al-Khersan H, Yannuzzi NA et al (2023) Aflibercept Monotherapy versus Bevacizumab-First for Diabetic Macular Edema: A Cost Analysis Based on Diabetic Retinopathy Clinical Research Network Protocol AC Results. Ophthalmol Retina 7(5):413\u2013419. https:\/\/doi.org\/10.1016\/j.oret.2022.11.010","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"7492_CR20","doi-asserted-by":"publisher","first-page":"e0197670","DOI":"10.1371\/journal.pone.0197670","volume":"13","author":"F van Asten","year":"2018","unstructured":"van Asten F, Michels CTJ, Hoyng CB et al (2018) The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective. PLoS ONE 13(5):e0197670. https:\/\/doi.org\/10.1371\/journal.pone.0197670","journal-title":"PLoS ONE"},{"key":"7492_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ajo.2020.07.010","volume":"223","author":"GC Brown","year":"2021","unstructured":"Brown GC, Brown MM, Rapuano SB, Boyer DA, Cost-Benefit (2021) Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States. Am J Ophthalmol 223:405\u2013429. https:\/\/doi.org\/10.1016\/j.ajo.2020.07.010","journal-title":"Am J Ophthalmol"},{"key":"7492_CR22","doi-asserted-by":"publisher","unstructured":"Stewart MW (2013) Review of Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration. Clin Med Insights: Ther 5. https:\/\/doi.org\/10.4137\/CMT.S8921","DOI":"10.4137\/CMT.S8921"},{"issue":"2","key":"7492_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","volume":"123","author":"WL Clark","year":"2016","unstructured":"Clark WL, Boyer DS, Heier JS et al (2016) Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. Ophthalmology 123(2):330\u2013336. https:\/\/doi.org\/10.1016\/j.ophtha.2015.09.035","journal-title":"Ophthalmology"},{"issue":"12","key":"7492_CR24","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"issue":"11","key":"7492_CR25","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","volume":"123","author":"JS Heier","year":"2016","unstructured":"Heier JS, Korobelnik JF, Brown DM et al (2016) Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology 123(11):2376\u20132385. https:\/\/doi.org\/10.1016\/j.ophtha.2016.07.032","journal-title":"Ophthalmology"},{"issue":"1","key":"7492_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik JF, Holz FG, Roider J et al (2014) Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. Ophthalmology 121(1):202\u2013208. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.012","journal-title":"Ophthalmology"},{"issue":"3","key":"7492_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1001\/jamaophthalmol.2022.6142","volume":"141","author":"DW Hutton","year":"2023","unstructured":"Hutton DW, Glassman AR, Liu D, Sun JK, DRCR Retina Network (2023) Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. JAMA Ophthalmol 141(3):268\u2013274. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.6142","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"7492_CR28","doi-asserted-by":"publisher","first-page":"608","DOI":"10.18553\/jmcp.2018.24.7.608","volume":"24","author":"L Hernandez","year":"2018","unstructured":"Hernandez L, Lanitis T, Cele C et al (2018) Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis. J Manag Care Spec Pharm 24(7):608\u2013616. https:\/\/doi.org\/10.18553\/jmcp.2018.24.7.608","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"7492_CR29","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, von Lundh P, Foxton R et al (2016) Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med 8(11):1265\u20131288. https:\/\/doi.org\/10.15252\/emmm.201505889","journal-title":"EMBO Mol Med"},{"issue":"5","key":"7492_CR30","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen AM, Ricci F, Paris LP et al (2021) Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye (Lond) 35(5):1305\u20131316. https:\/\/doi.org\/10.1038\/s41433-020-01377-x","journal-title":"Eye (Lond)"},{"issue":"5","key":"7492_CR31","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00417-024-06695-4","volume":"263","author":"V Chaudhary","year":"2025","unstructured":"Chaudhary V, Mar F, Amador MJ et al (2025) Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases. Graefes Arch Clin Exp Ophthalmol 263(5):1239\u20131247. https:\/\/doi.org\/10.1007\/s00417-024-06695-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"7492_CR32","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A et al (2024) TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology 131(8):914\u2013926. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.014","journal-title":"Ophthalmology"},{"issue":"10326","key":"7492_CR33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP et al (2022) Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet 399(10326):741\u2013755. https:\/\/doi.org\/10.1016\/S0140-6736(22)00018-6","journal-title":"Lancet"},{"issue":"3","key":"7492_CR34","doi-asserted-by":"publisher","first-page":"100302","DOI":"10.1016\/j.xops.2023.100302","volume":"3","author":"LO Hattenbach","year":"2023","unstructured":"Hattenbach LO, Abreu F, Arrisi P et al (2023) BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale. Ophthalmol Sci 3(3):100302. https:\/\/doi.org\/10.1016\/j.xops.2023.100302","journal-title":"Ophthalmol Sci"},{"issue":"8","key":"7492_CR35","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","volume":"131","author":"R Tadayoni","year":"2024","unstructured":"Tadayoni R, Paris LP, Danzig CJ et al (2024) Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials. Ophthalmology 131(8):950\u2013960. https:\/\/doi.org\/10.1016\/j.ophtha.2024.01.029","journal-title":"Ophthalmology"},{"key":"7492_CR36","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.2147\/OPTH.S384995","volume":"16","author":"EA Meer","year":"2022","unstructured":"Meer EA, Oh DH, Brodie FL (2022) Time and Distance Cost of Longer Acting Anti-VEGF Therapies for Macular Degeneration: Contributions to Drug Cost Comparisons. Clin Ophthalmol 16:4273\u20134279. https:\/\/doi.org\/10.2147\/OPTH.S384995","journal-title":"Clin Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07492-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07492-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07492-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:26:29Z","timestamp":1788499589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07492-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":36,"alternative-id":["7492"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07492-x","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"4 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study is exempt from informed consent. The data reviewed is a secondary analysis of existing data, does not involve intervention or interaction with human subjects, and is de-identified per the de-identification standard defined in Section \u00a7 164.514(a) of the HIPAA Privacy Rule. The process by which the data is de-identified is attested to through a formal determination by a qualified expert as defined in Section \u00a7 164.514(b)(1) of the HIPAA Privacy Rule. This formal determination by a qualified expert refreshed on December 2020.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflicting relationships exist for any author.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}